ADMA Biologics Inc vs Ferrari NV — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Ferrari NV trades at $409.9 (market cap $71.67B). The key difference: Ferrari NV is far larger — about 32.3× ADMA Biologics Inc's market cap, and Ferrari NV pays a 1.04% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | RACE | |
|---|---|---|
Market Cap | $2.22B | $71.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $504.09 |
52-Week Low | $7.60 | $314.63 |
Enterprise Value | $2.29B | $73.60B |
Dividend Yield | — | 1.04% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Ferrari (RACE) trades at $407.21, up 0.11% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $2.99, beating estimates of $2.83, and raised full-year guidance, driven by robust personalization demand and pricing power. Revenue growth has been consistent, with 2025 revenue at $7.15 billion and net income margin of 22.25%, though valuation multiples like P/E of 37.93 are elevated.
The outlook remains positive given earnings beats, raised guidance, and analyst consensus favoring buys, but risks include high valuation sensitivity and economic cyclicality. Upside to the $462.67 price target depends on sustained premium demand execution.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →